文献速递肿瘤 PET/CT骨显像与常规 SPECT

转移性前列腺癌中18F-氟化钠PET/CT与PSMA靶向18F-DCFBC PET/CT的前瞻性比较

A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer.
PubMed 文献 · J Nucl Med · 2018-03-30

28例经传统影像确诊转移的前列腺癌患者前瞻性接受基线及随访18F-DCFBC与18F-NaF PET/CT,中位随访5.7个月。基线241个病灶中56个为仅18F-DCFBC检出的软组织病灶,18F-NaF检出骨病灶显著多于18F-DCFBC(P<0.001)。作者认为PSMA靶向成像的效用似乎取决于患者病程与治疗状态。

要点

  • 18F-NaF检出骨病灶显著多于18F-DCFBC(P<0.001)。
  • PSA与18F-DCFBC的SUV指标强相关(ρ>0.5,P<0.01),与18F-NaF相关性差(ρ<0.3,P>0.1)。
  • PSA<2 ng/mL且接受雄激素剥夺治疗者18F-NaF病灶多于18F-DCFBC(P=0.02)。

核心结论

  • PSMA靶向成像在转移性前列腺癌中的效用似乎取决于患者病程与治疗状态。
  • 与18F-NaF PET/CT相比,18F-DCFBC PET/CT在早期或转移性去势敏感性疾病的治疗状态下检出的骨病灶显著更少。
  • 在晚期转移性去势抵抗性前列腺癌中,18F-DCFBC PET/CT与NaF PET/CT显示良好一致性。

研究设计与样本

  • 前瞻性队列研究,纳入28例经传统影像确诊转移的前列腺癌患者。
  • 所有患者完成基线18F-DCFBC PET/CT与18F-NaF PET/CT,23例完成随访影像,中位随访间隔5.7个月(范围4.2–12.6个月)。
  • 在每个时间点比较两种PET/CT药物的病灶检出,并用非参数检验(Spearman相关、Wilcoxon秩和)将检出及SUV特征与基线时血清PSA水平和治疗状态比较。

主要发现

  • 26例在基线时经18F-NaF或18F-DCFBC检出转移灶,2例两种扫描均阴性,3例为仅软组织病变。
  • 基线共检出241个病灶,其中56个为仅18F-DCFBC识别的软组织病灶,185个为18F-NaF或18F-DCFBC检出的骨病灶。
  • 18F-NaF检出的骨病灶显著多于18F-DCFBC(P<0.001)。
  • PSA与患者水平SUV指标的相关性在18F-DCFBC中强(ρ>0.5,P<0.01),在18F-NaF中差(ρ<0.3,P>0.1)。
  • PSA低于中位水平(<2 ng/mL)且接受雄激素剥夺治疗者(n=11)18F-NaF病灶多于18F-DCFBC(P=0.02);PSA>2 ng/mL且接受雄激素剥夺治疗者(n=8)18F-DCFBC病灶等于或多于18F-NaF。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this study was to compare the diagnostic performance of 18F-DCFBC PET/CT, a first-generation 18F-labeled prostate-specific membrane antigen (PSMA)-targeted agent, and 18F-NaF PET/CT, a sensitive marker of osteoblastic activity, in a prospective cohort of patients with metastatic prostate cancer. Methods: Twenty-eight prostate cancer patients with metastatic disease on conventional imaging prospectively received up to 4 PET/CT scans. All patients completed baseline 18F-DCFBC PET/CT and 18F-NaF PET/CT scans, and 23 patients completed follow-up imaging, with a median follow-up interval of 5.7 mo (range, 4.2-12.6 mo). Lesion detection was compared across the 2 PET/CT agents at each time point. Detection and SUV characteristics of each PET/CT agent were compared with serum prostate-specific antigen (PSA) levels and treatment status at the time of baseline imaging using nonparametric statistical testing (Spearman correlation, Wilcoxon rank). Results: Twenty-six patients had metastatic disease detected on 18F-NaF or 18F-DCFBC at baseline, and 2 patients were negative on both scans. Three patients demonstrated soft tissue-only disease. Of 241 lesions detected at baseline, 56 were soft-tissue lesions identified by 18F-DCFBC only and 185 bone lesions detected on 18F-NaF or 18F-DCFBC. 18F-NaF detected significantly more bone lesions than 18F-DCFBC (P < 0.001). Correlation of PSA with patient-level SUV metrics was strong in 18F-DCFBC (ρ > 0.5, P < 0.01) and poor in 18F-NaF (ρ < 0.3, P > 0.1). When PSA levels were combined with treatment status, patients with below-median levels of PSA (<2 ng/mL) on androgen deprivation therapy (n = 11) demonstrated more lesions on 18F-NaF than 18F-DCFBC (P = 0.02). In PSA greater than 2 ng/mL, patients on androgen deprivation therapy (n = 8) showed equal to or more lesions on 18F-DCFBC than on 18F-NaF. Conclusion: The utility of PSMA-targeting imaging in metastatic prostate cancer appears to depend on patient disease course and treatment status. Compared with 18F-NaF PET/CT, 18F-DCFBC PET/CT detected significantly fewer bone lesions in the setting of early or metastatic castrate-sensitive disease on treatment. However, in advanced metastatic castrate-resistant prostate cancer, 18F-DCFBC PET/CT shows good concordance with NaF PET/CT.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Harmon SA, Bergvall E, Mena E, et al. A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer. J Nucl Med. 2018. PMID: 29602821. doi:10.2967/jnumed.117.207373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。